Neurogene
NGNE
86 hedge funds and large institutions have $581M invested in Neurogene in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 2 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 2
30% more funds holding
Funds holding: 66 → 86 (+20)
20% more capital invested
Capital invested by funds: $483M → $581M (+$98.4M)
4.4% more ownership
Funds ownership: 102.2% → 106.6% (+4.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.22M |
| 3 |
Jennison Associates
New York
|
+$3.05M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.56M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$4.86M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.65M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.91M |
| 5 |
Walleye Capital
New York
|
-$1.86M |
NGNE Hedge Fund Activity: Q3 2024 in Review
86 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2024, worth a combined $581M — up 20% from $483M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NGNE positions and 2 closed out — a net gain of 20 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.6M. The largest seller was Avidity Partners Management, cutting an estimated $11.7M.
- 86 institutional investors held Neurogene (NGNE) as of Q3 2024, up from 66 in Q2 2024.
- Funds reported $581M of Neurogene stock for Q3 2024, up 20% quarter-over-quarter.
- 22 funds opened new Neurogene positions in Q3 2024 and 2 closed out, a net change of +20 holders.
- The largest Neurogene buyer in Q3 2024 was Fidelity Investments, an estimated $25.6M added.
- The largest Neurogene seller in Q3 2024 was Avidity Partners Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2024.